HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4737 Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors. Dec 18 2024
S8593 VX-984 VX-984 (M9831) is an orally active, potent, selective, and ATP-competitive inhibitor of DNA-PK. VX-984 effectively suppresses non-homologous end joining (NHEJ) and increases DNA double-strand breaks (DSBs). It enhances the cytotoxic effects of ionizing radiation (IR) in various cancer cell lines, including non-small cell lung cancer (NSCLC) cell lines, in vitro. Additionally, VX-984 reduces DNA-PKcs autophosphorylation. Dec 18 2024
E1462 P62-mediated mitophagy inducer P62-mediated mitophagy inducer (PMI) is a P62-mediated activator of mitophagy that functions independently of parkin recruitment or mitochondrial membrane potential (ΔΨm) collapse. It remains effective even in cells lacking a fully functional PINK1/Parkin pathway. PMI stabilizes Nrf2 and enhances p62 expression, thereby activating mitophagy. Dec 18 2024
E6024 Selumetinib sulfate Selumetinib sulfate (AZD6244 sulfate, ARRY-142886 sulfate) is an oral, non-ATP-competitive inhibitor of MEK1/2, with an IC50 of 14 nmol/L against purified MEK1. It exhibits an anti-tumor effect in the HT-29 xenograft model and is used to treat cancer and inflammation. Dec 18 2024
E4781 OPN expression inhibitor 1 OPN Expression Inhibitor 1 (Compound 11) is a DHA ether derivative containing a 1,2,3-triazole ring that effectively inhibits osteopontin (OPN) expression. It exhibits significant potential as an anticancer agent by specifically targeting OPN, a key factor in breast cancer progression and metastasis. Dec 16 2024
E1974 MS8709 MS8709 (EX-A11295) is a first-in-class G9a/GLP proteolysis targeting chimera (PROTAC) degrader, that induces G9a/GLP degradation in a concentration, time, and ubiquitin-proteasome system (UPS)-dependent manner, and does not alter the mRNA expression of G9a/GLP over other methyltransferases. It displays superior cell growth inhibition in prostate, leukemia, and lung cancer cells over parent G9a/GLP inhibitors. Dec 16 2024
E4771 Aprocitentan Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively. Dec 16 2024
E1984 JBJ-09-063 hydrochloride JBJ-09-063 hydrochloride is a mutant-selective allosteric inhibitor of EGFR with IC50 values of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S, respectively. JBJ-09-063 hydrochloride significantly inhibits the phosphorylation of EGFR, Akt, and ERK1/2. Dec 16 2024
E1863 Inixaciclib Inixaciclib (NUV-422) is a potent inhibitor of CDK2, CDK4, and CDK6. It inhibits the growth of glioma cell lines in vitro and exhibits antitumor activity in GB xenograft models, PDX models of HR+ HER2- metastatic breast cancer resistant to CDK4/6 inhibitors and prostate cancer resistant to anti-androgens. Dec 12 2024
E1941 ACT-1016-0707 ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases. Dec 12 2024
E4738 LYMTAC-2 LYMTAC-2 is a lysosomal-targeting chimera (LYMTAC) designed to degrade membrane-associated proteins by leveraging lysosomal membrane proteins (LMPs) like RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with its target protein, such as KRASG12D, and facilitates relocalization to the lysosome, leading to ubiquitin-dependent degradation. It has the potential to study membrane protein regulation and develop strategies to overcome resistance in KRAS-driven signaling pathways. Dec 12 2024
E4612 iCARM1 iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research. Dec 12 2024
E6011 Agomelatine hydrochloride Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. It is also a selective antagonist of 5-HT2C receptors with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively. Blockade of these receptors enhances adrenergic and dopaminergic transmission in the frontocortical regions. Dec 12 2024
E1921 NRL-1049 NRL-1049(BA 1049) is a small molecule selective inhibitor of ROCK2 with an IC50 of 0.59 µM. It exhibits potent efficacy in preserving the blood-brain barrier (BBB) and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice. Dec 12 2024
E4782 17-OH PREG (17a-Hydroxypregnenolone) 17-OH PREG (17a-Hydroxypregnenolone) is a pregnenolone metabolite and DHEA precursor. It is formed through CYP17A1 hydroxylase and 17,20-lyase activities. It is the most relevant steroid for the study of elevated plasma levels linked to type II 3β-hydroxysteroid dehydrogenase deficiency. Dec 12 2024
E5775 Exatecan Exatecan (DX-8951), is a water-soluble derivative of camptothecin. It acts as an inhibitor of DNA topoisomerase I with an IC50 value of 1.906 μM. It demonstrates potent antitumor effects and triggers apoptotic cell death after treatment in human pancreatic cancer cells. Dec 11 2024
E4997 BAY 2927088（Sevabertinib） BAY 2927088（Sevabertinib) is the first non-covalent, potent, oral, selective, and reversible inhibitor of tyrosine kinase that potently inhibits mutant HER2 and mutant EGFR in preclinical models. It targets Exon 20 insertions in non-small-cell lung carcinoma (NSCLC) patients. Dec 11 2024
E5777 Tris(benzyltriazolylmethyl)amine Tris(benzyltriazolylmethyl)amine (TBTA) is a ligand used as a biochemical tool for labeling proteins and enzymes. It dramatically enhances the Copper(II) acetate (Cu(OAc)2)-accelerated azide-alkyne cycloaddition (AAC) reactions involving nonchelating azides. Dec 11 2024
E5767 Ovalbumins Ovalbumin is a major glycoprotein found in egg whites, serving as a nutrient reserve for developing embryos and used in the food industry. It also induces a Th2 immune response in sensitized individuals, characterized by the production of cytokines like IL-4, IL-5, and IL-13, leading to airway inflammation, hyper-responsiveness (AHR), and immune cell infiltration, key features in asthma models. Dec 11 2024
P1246 ODN 1826 sodium ODN 1826 sodium (CpG 1826 sodium) is a synthetic CpG oligodeoxynucleotide and agonist of TLR9 signaling pathway, that induces G1-phase arrest and apoptosis in A20 lymphoma cells while stimulating NO and iNOS production in mouse models, as part of its immunostimulatory activity. Dec 11 2024